Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2011

Discontinued Operations [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

Dispositions

On April4, 2011, the company sold, in separate transactions, its Athena Diagnostics business (Athena) for $740 million in cash and its Lancaster Laboratories business (Lancaster) for $180 million in cash and escrowed proceeds of $20 million, due in October 2012. The sale of these businesses resulted in an after-tax gain of approximately $304million or $0.79 per diluted share. Athena provides diagnostic testing for neurological and other diseases, with an emphasis on gene-based tests. Lancaster is a contract-testing laboratory that provides analytical laboratory services. The results of both businesses have been included in the accompanying financial statements as discontinued operations for all periods presented. Operating results and balance sheet data of these businesses were as follows:

(In millions)	2011		2010			2009
Revenues	$	54.3	$	226.2		$	205.3
Pre-tax Income		9.1		58.9			46.6
					December 31,
						2010
Other Current Assets						$	64.8
Other Assets							451.0
Other Accrued Expenses							17.6
Other Long-term Liabilities							58.4

       Operating results of the laboratory workstations business were as follows:

(In millions)	2011		2010		2009
Revenues	$	179.6	$	185.8	$	179.0
Pre-tax Income (Loss)		(6.2)		18.0		26.6